melfalan medac
medac gesellschaft fur klinische spezialpraparate mbh - melfalan - melfalan
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mieloma multiplo - agenti antineoplastici - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
bortezomib teva
teva italia s.r.l. - bortezomib - bortezomib
bortezomib sandoz gmbh
sandoz gmbh - bortezomib - bortezomib
bortezomib eg
eg s.p.a. - bortezomib - bortezomib
bortezomib zentiva
zentiva italia s.r.l. - bortezomib - bortezomib
bortezomib mylan
mylan s.p.a. - bortezomib - bortezomib
bortezomib dr. reddy's
dr. reddy s s.r.l. - bortezomib - bortezomib